immunomodulator Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1/2 (1)

Interventional (1)

GWT-TUD GmbH (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadcancer

I am/have/hadpancreatic ductal adenocarcinoma

I am/have/hadpancreatic cancer

I am/have/haddrug test

I am/have/hadadenocarcinoma

I am/have/hadpdac

I am/have/hadpaclitaxel/gemcitabine

I am/have/hadductal adenocarcinoma

I am/have/hadbreast ductal carcinoma

I am/have/hadpancreatic adenocarcinoma

I am/have/hadmeasurable disease

I am/have/hadmetastasis

added new label for I am/have/had

more

I am looking for

I am looking forlenalidomide

I am looking forblockade

I am looking forazacitidine

I am looking forromidepsin

I am looking forgemcitabine

I am looking forpaclitaxel

I am looking forantineoplastic

I am looking forantineoplastic agents

I am looking fordurvalumab

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

lenalidomide

pancreatic ductal adenocarcinoma

adenocarcinoma

paclitaxel/gemcitabine

ductal adenocarcinoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.